Given by injection every four weeks, the drug offers an extra option for patients with the most severe symptoms, including those who suffer multiple asthma attacks. In April, NICE’s appraisal ...

To determine whether treatment of occult acid reflux is worthwhile for asthma patients, 412 adults with inadequately controlled asthma were randomized to receive the proton-pump inhibitor (PPI ...

It was originally approved in 2003 for the treatment of moderate to severe asthma. The drug was subsequently granted marketing authorization to treat chronic spontaneous urticaria and ...

Despite changes in the approach to treatment and evidence-based medications to manage ... of the blue Saba reliever pump is a serious problem for South African asthma patients.

One in three people with asthma uses medication daily, one of them being Montelukast, more commonly known by its generic name Singulair. It is usually prescribed when asthma is mild and can stop ...

Both drugs target eosinophils, the immune cells which trigger severe asthma symptoms in some patients. Teva gained the prized recommendation after confidential discount persuaded NICE to change ...

AstraZeneca is adding to the thesis that the drug can cut the risk of asthma exacerbations regardless of disease severity. In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose ...

and following with a readout from a mid-stage study in asthma the following year, according to its IPO filing. The drug involved in those trials, verekitug, targets a protein called TSLP that ...